A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing

NCT03133650 | Active Not Recruiting Phase 1 FDA Drug

• 1 other identifier: 15-319
• Study Type: interventional
• Target: 12
• Locations: 2 countries
• Sites: 3

Brief Summary

The purpose of this study is to establish the highest dose of laser light for WST-11 VTP to treat obstruction from esophageal cancer that can be safely given.

Conditions

Esophagogastric Cancer; Moderate to Severe Dysphagia

Keywords

Vascular-Targeted Photodynamic Therapy (VTP); 15-319

Outcome Measures

Primary Outcomes (1)

• Maximum tolerated laser fluence rate

  The maximally tolerated laser light fluence rate (mW/cm) of light exposure for VTP of malignant obstruction due to esophagogastric cancer will be measured by examining 6 fluence rates beginning with a fluence rate of 150 nW/cm, then increasing by 50mW/cm, up to a maximum of 400 mW/cm (150, 200, 250 300, 350, 400).

  60 days

Study Arms (1)

Vascular-targeted photodynamic therapy (VTP) using WST11

EXPERIMENTAL

Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.

Drug: WST 11-mediated VTP therapy

Interventions

WST 11-mediated VTP therapy DRUG

Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.

Vascular-targeted photodynamic therapy (VTP) using WST11

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 or older
• Confirmed tissue diagnosis of esophageal squamous cell cancer, adenocarcinoma or poorly differentiated carcinoma, with pathology reviewed at MSKCC
• Has incurable disease defined as at least one of the following:
• Presence of metastases to other organs (Stage IV), now or previously
• Has locally advanced disease and are not candidates for surgery or more radiation treatment
• Has received the maximal radiation therapy to the primary site, or has been assessed by radiation oncology as not being a candidate for chemoradiation therapy.
• Karnofsky performance status \>/= 50%
• No endoluminal stent in place at the time of treatment
• Previous esophageal dilation is permitted, provided the patient has developed recurrent dysphagia since that procedure
• Patients should not have received any systemic therapy (including chemotherapy, biologic therapy or immunotherapy) \</= 7 days prior to treatment
• Prior radiation or surgery to the esophagus is permitted for patients with locally recurrent/persistent disease
• Patients on prophylactic or full-dose anticoagulation are eligible, provided the treating physician believes it is safe to temporarily withhold anticoagulation (see Section 9.2)
• Adequate organ function defined at baseline as:
• ANC ≥1,000/ L
• Platelets ≥75,000/ L

You may not qualify if:

• Pregnant or breast-feeding women. Women of childbearing potential (WOCBP) must undergo a negative pregnancy test (either serum or urine) prior to study entry. Both sexes must use contraception while on study. WOCBP include:
• Any woman who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or oophorectomy) or who is not post-menopausal (defined as amenorrheic ≥12 consecutive months)
• Women on hormone replacement therapy with documented serum follicle stimulating hormone level \> 35 mIU/ml
• Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as intrauterine device or barrier methods to prevent pregnancy or are practicing abstinence of where the partner is sterile
• T4 tumors with involvement of any adjacent structure, including the trachea, aorta or pleura
• Prior history of esophageal perforation
• Any other medical or psychiatric comorbidities, including decompensated heart failure, unstable angina or coronary artery disease or severe pulmonary disease, that, in the opinion of the study investigator, would make the patient a poor candidate for the study

Sponsors & Collaborators

• Weizmann Institute of Science: collaborator
• Steba Biotech S.A.: collaborator
• Memorial Sloan Kettering Cancer Center: lead

Study Sites (3)

Memorial Sloan - Kettering Cancer Center

New York, New York, 10021, United States

Location

Weill Cornell Medical Center (Data Analysis Only)

New York, New York, 10021, United States

Location

Weizmann Institute of Science

Rehovot, Israel

Location

Related Links

• Memorial Sloan Kettering Cancer Center

Study Officials

• Hans Gerdes, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 26, 2017
• First Posted: April 28, 2017
• Study Start: April 26, 2017
• Primary Completion (Estimated): February 23, 2027
• Study Completion (Estimated): February 23, 2027
• Last Updated: April 16, 2026

Record last verified: 2026-04

Locations

US (2); IL (1)